TOPLINE:

Lisocabtagene maraleucel demonstrated superior efficacy with median event-free survival of 29.5 months compared to 2.4 months for standard of care in second-line large B-cell lymphoma (LBCL). The 36-month overall survival rate reached 63% for lisocabtagene maraleucel vs 52% for standard care, with progression-free survival rates of 51% vs 26.5%, respectively.

METHODOLOGY:

A total of 184 adults eligible for autologous stem cell transplantation were randomly assigned 1:1 to receive either lisocabtagene maraleucel or standard of care.

Participants in the lisocabtagene maraleucel arm received a target dose of 100 × 10 6 chimeric antigen receptor-positive (CAR) T cells, while the standard-of-care arm received three cycles of protocol-defined immunochemotherapy, followed by high-d

See Full Page